INTRODUCTION
Calpains and caspases are cysteine proteases that are ubiquitous in vertebrate cells. Degradation of proteins by these two proteases is associated with many cellular pathways, including long term potentiation in neurons [1] , cell motility and apoptosis [2] amongst others. Over 100 proteins, including spectrin [3] , are calpain substrates [2, 4, 5] . Calpains are activated by an elevation of the calcium concentration, with micromolar Ca 2+ concentrations for calpain 1 (μ-calpain) and millimolar Ca 2+ concentrations for calpain 2 (m-calpain) [6] . These two calpains are most well-studied. Their activities are negatively regulated by a specific endogenous peptide inhibitor calpastatin [7] , as well as several non-specific inhibitors [8] . The inhibitor Cerebrolysin has been shown to improve neurodegenerative dementia caused by Alzheimer's disease and to accelerate the overall restoration of function after acute brain ischemia [9] . Caspases are essential in the initiation and execution of apoptosis [10] , and they account for the majority of cellular and morphological events that occur during cell death [11, 12] . Regulation of activities of both calpain and caspase with inhibitors may provide means to manipulate signal pathways and to protect neural cells from degeneration [8, 13, 14] . Spectrin is a major component of the cytoskeleton in a wide range of cells, including neurons. The αand β-spectrins associate to form an αβ dimer, and two dimers form a functional (αβ) 2 tetramer [15] . In humans the known isoforms consist of erythroid α-spectrin (αI), non-erythroid (brain) α-spectrin (αII), erythroid β-spectrin (βI), non-erythroid β-spectrin (βII), and other β-spectrins. The spectrin isoforms are potential targets for both calpain and caspase actions during cell morphology change and apoptosis. Different spectrin isoforms show different susceptibility toward these two enzymes. For example, calpain does not cleave αI, but cleaves βI at a single site, W2061-A2062 [16] , αII at two sites, Y1176-G1177 and G1230-S1231 and βII at four sites, Q1440-S1441, S1447-Q1448, L1482-A1483 and A2066-2067 [17, 18] . Caspase does not cleave αI and βI but cleaves αII at two sites, D1185-S1186 and D1478-S1479 [19] and βII at two sites, D1457-S1458 and D2146-S2147 [20] . The cleavage of αII spectrin produces two fragments (150 and 145 kDa), known as the spectrin break down products, which are used as markers of traumatic brain injury [21] .
The tetramerization region on α-spectrin is at the N-terminus while on β-spectrin is at the C-terminus. The solution NMR structure of an αI fragment consisted of the first 156 amino acid residues (αI-N1) shows a partial domain with first 20 residues unstructured followed by a single coiled coil helix (residues 21-45) [22] . A five-residue unstructured junction region (residues 46-51) connects the partial domain to the first triple helical structural domain (residues 52-156). Another αI fragment that extends the αI-N1 to consist of the second and third structural domains (αI-N3) [23] , as well as similar fragments of αII, αII-N3 [24] and αII-N1 [23] have also been studied. The β-spectrin C-terminal fragment of βI residues 1898-2083 (βI-C1) [22] , or βII residues 1906-2093 (βII-C1) [25] , consists of the last structural domain of β-spectrin, followed by the two-helix partial domain, and have been used as model protein to study spectrin tetramer formation. In this study, we report an inhibitory effect of these fragments (αI-N1, αI-N3, αII-N1, αII-N3, βI-C1 and βII-C1) on the activity of calpain, but not caspase.
MATERIALS AND METHODS

Chemicals
Calpain 1 (μ-calpain, human erythrocytes), casein, calpastatin and 3-[(3cholamido-propyl) dimethylammonio]-1-propanesulfonate (CHAPS) were from Calbiochem (La Jolla, CA); caspase-3 (human recombinant) and N-acetyl-Asp-Glu-Val-Asp-p-nitro-aniline (Ac-DEVD-pNA) were from Biomol (Plymouth Meeting, PA).
Protein samples
Six recombinant spectrin proteins, αI-N1, αI-N3, αII-N1, αII-N3, βI-C1, and βII-C1 were expressed and purified following standard laboratory procedures [23] . Glutathione (GSH) is known to inhibit calpain activity [26] and was used in protein purification. The protein samples were applied to a gel filtration column to remove GSH, though GSH in some samples containing cysteine residues was difficult to remove [27] . Two of the spectrin fragments (αI-N1 and αII-N1) consisted of no cysteine residues and thus should have little residual GSH. The protein samples in 5 mM phosphate buffer at pH 7.4 with 150 mM NaCl (PBS) were concentrated to 200-300 μM, and extensively dialyzed against PBS overnight prior to assay measurements. The samples of different spectrin fragments were dialyzed in the same physical buffer to ensure that all protein samples were in the same solution conditions. The PBS buffer used for dialysis was saved and used to prepare controls in the assays. Some protein samples, along with their PBS buffer used for dialysis, were frozen for storage, thawed and centrifuged to remove particulate, if any, before the assay. Polyacrylamide gel electrophoresis, with 16% acrylamide in SDS, was used to assess protein purity [23] .
Calpain colorimetric assay
Published calpain assay procedures [9] were followed, except that the calpain concentration (0.11 μM) was two times lower, but 5 times higher than recommended by the manufacturer. Briefly, the calpain reaction solutions consisted of μ-calpain (0.4 μl; 0.11 μM), casein (10 ml; 85 μM), imidazole (10 μl; 0.1 M), CaCl 2 (10 μl; 5 μM -5 mM), cysteine (10 μl; 5 mM), water and PBS buffer (40 μl), spectrin in PBS (40 μl; 20 -250 μM), or calpastatin in PBS (40 μl; 150 nM). The total reaction solution volume was 100 μl. The absorbance value at 750 nm (A 750 ) of the assay solution was measured. The activity ratio of a sample with spectrin was calculated from its A 750 value divided by the A 750 value of a sample with equal volume of PBS, but no spectrin. A value of 1 was expected if no inhibition was observed. The reaction mixture was initially incubated at different temperatures and times to determine optimal conditions for spectrin inhibition.
Caspase colorimetric assay
The hydrolysis of caspase-3 substrate Ac-DEVD-pNA produces pNA. The concentrations of pNA, with and without spectrin fragments, were monitored spectroscopically at 405 nm [28] . Quantitatively, caspase in HEPES buffer was diluted with HEPES buffer (50 mM, with 100 mM NaCl, 0.5% CHAPS, 1 mM EDTA, 10% glycerol and 10 mM DTT at pH 7.4) to give a solution of 10 U/μl, with 1U defined as the activity of turning over 1 pmol of Ac-DEVD-pNA to pNA in 1 min. The substrate, Ac-DEVD-pNA (100 mM), was dissolved in DMSO, and this solution (1 ml) was diluted with HEPES buffer to 400 μM. The diluted caspase solution (5 μl), Ac-DEVD-pNA (51 μl) and HEPES buffer (144 μl) were mixed and divided into three equal portions. To each portion, HEPES, PBS, or spectrin fragments at different concentrations in PBS (30 μl) was added to give "HEPES sample", "PBS sample" or "spectrin sample", respectively. This practice of using triplet samples allowed us to monitor the effects of spectrin fragments directly since all three sample consisted of the exact same amounts of caspase (5U) and its substrate Ac-DEVD-pNA (68 μM). Three different spectrin fragments (αI-N3, αII-N1 and αII-N3) were used. When the hydrolysis reaction was completed (22 hrs), the absorbance value at 405 nm (A 405 ) of each of triplet was obtained, and converted to pNA concentrations using an extinction coefficient of 10,500 M -1 cm -1 [28] .
RESULTS AND DISCUSSION
To optimize spectrin inhibition conditions, we first varied the Ca 2+ concentration in the assay solution from 2 μM to 5 mM, and found, not surprisingly, that about 50 μM of Ca 2+ was sufficient for full μ-calpain activity in the absence of spectrin (Fig. 1A) . However, to be consistent with other published results [6] , we continued to perform calpain assays with a Ca 2+ final concentration of 5 mM. We then performed the calpain reactions in the presence of a spectrin fragment, αII-N1, at two different concentrations (17 and 48 μM), and at different temperatures (10-40 o C). We found reduced calpain activities at both concentrations, with more reduction at a higher concentration. The activity ratio (activity in a sample with spectrin fragment/activity without spectrin fragment, see Methods) was about 0.7 for samples with 17 μM αII-N1 and only about 0.1 for samples with 48 μM αII-N1, at 10 o C (Fig. 1B) . Furthermore, the effect was slightly temperature dependent at both concentrations, with a maximum activity ratio (least inhibition) around 25-30 o C (Fig. 1B) . All remaining assays were carried out on samples with calpain reaction at 30 o C. We also varied incubation time period of the calpain reaction in the presence of αII-N1 (68 μM) at 30 o C. The activity ratio was about 0.5 after 5 min incubation and leveled off to about 0.25 after about 15 min (Fig. 1C ). To ensure reaction completion, we used 30 min incubation time for all other assays. Finally, we varied the concentration of spectrin fragments in the calpain reaction mixture. A clear concentration dependent effect was observed for αII-N1 (Fig. 1D ). Furthermore, a longer spectrin fragment, αII-N3, and a βI-spectrin fragment of similar size to αII-N1, βI-C1, appeared to exhibit similar concentrationdependent effect as αII-N1. At saturating concentrations (50-80 μM), the activity ratios were about 0.2-0.4. In samples with a spectrin fragment at 50 μM, the spectrin to casein (substrate) ratio was about 0.6. Gel electrophoresis results of representative proteins showed that the proteins used were with high purity (inset of Fig. 1D ). Erythroid α-spectrin fragments (αI-N1 and αI-N3) and non-erythroid β-spectrin fragment (βII-C1) exhibited similar inhibitory effects (Fig. 2) . Activity ratio was about 0.25 at saturating concentrations (about 80 μM) of α-spectrin fragments, and about 0.4 for β-spectrin fragments. We also tested the inhibition effect of calpastatin, a well known endogenous calpain inhibitor [29] , under our assay conditions and found that the activity ratio was about 0.3 in the presence of 150 nM calpastatin. To test whether any protein will inhibit such inhibitory effect, we used BSA in same solution conditions and found no effect on calpain activity. Results of protein gel electrophoresis performed on assay samples showed that the spectrin fragments remained intact (data not shown), indicating that the spectrin fragments were not cleaved by calpain. We observed no inhibitory effect on caspase activity by the same α-spectrin fragments at the same concentration (about 80 μM). It should be noted that the spectrin/caspase ratio was about 35 times higher than spectrin/calpain ratio. For αI-N3 triplet samples (see Methods for the definition of the triplet samples), the average concentration of caspase cleavage product, pNA, was 78.2 ± 2.0 μM (n = 3) for HEPES samples, 69.7 ± 5.1 μM for PBS samples, and 81.0 ± 4.5 μM for αI-N3 in PBS. Similarly, for αII-N1 triplet samples, the average concentration of pNA was 79.4 ± 10.7 μM for HEPES samples, 68.6 ± 15.1 μM for PBS samples, and 80.4 ± 12.6 μM for αII-N1 in PBS samples. For αII-N3 triplet samples, the average concentration of pNA was 79.2 ± 0.7 μM for HEPES samples, 73.3 ± 5.7 μM for PBS samples, and 81.1 ± 1.8 μM for αII-N3 in PBS samples. These data indicate that there were no detectable differences in samples with and without spectrin fragments. In summary, with carefully controlled sample conditions, we showed a rather surprising, concentration dependent inhibitory effect on μ-calpain activities of both erythroid and non-erythroid α-spectrin N-terminal fragments, and β-spectrin C-terminal fragments. At saturating concentrations of spectrin fragments (about 50-80 μM), only about 30% calpain activity remained. However, no detectable spectrin effect was observed on caspase activity. These spectrin fragments were found not to be substrates of calpain. Thus, the spectrin fragments bind to calpain, either at the active site to inhibit the action of calpain on the substrate casein, or to induce a conformational change rendering an inactive calpain molecule. The spectrin fragments that we used all consisted of triple helical bundle structural domain(s) and a partial domain that consists of "non-bundled" coiled coil helices, with one such helix in the α-spectrin fragments and two in the β-spectrin fragments. Since the fragments consisted of three structural domains (αI-N3 and αII-N3) exhibited similar effects as the fragments consisted of only one structural domain (αI-N1 and αII-N1), we speculate that the partial domains in these fragments are responsible for the inhibitory effect. The structural requirements for substrate recognition by calpain are not well understood. A wide range of sequences have been found to flank known calpain cleavage sites, suggesting that calpain can accommodate a variety of side chains within its active site binding pocket [5] . It is generally considered that calpain probably recognizes global structural elements rather than specific primary sequences [5] . Analysis of published information on substrate proteins suggests that calpain cleaves within rather disordered segments of proteins, and interestingly, the segment C-terminal to the cleavage site resembles the consensus inhibitory region of calpastatin [5] . It appears that the binding of calpastatin to calpain induces an unstructured-to-helical conformational change in calpastatin [30] . Thus, it is possible that the spectrin partial domain helix/helices may bind the calpain active site. Calpain has been reported to bind near to the C-terminal coiled-coil domain of SNAP-23 [31] . As mentioned above, spectrin itself is a substrate of calpain [16, 17] , with the binding/cleavage site of non-erythroid α-spectrin in the middle part of the molecule at an unstructured loop region [3, 16] . Recently we proposed a structure of αII-N1 from spin-labeling electron paramagnetic resonance studies that is similar to αI-N1, except in αII-N1, the junction region is helical [24] . The βI-C1 and βII-C1 structures, though have not been reported, but through sequence homology analysis, is assumed to consist of two helices [25] . EPR studies support the helical conformation prediction in βI-C1 [32] , and CD studies show that the two helices are unpaired [33] . The αI-N1, αI-N3, αII-N1 and αII-N3 proteins serve as model systems to study the spectrin tetramerization process since these proteins associate with βI-C1 or βII-C1 proteins with affinity similar to those of intact a and b association [23, 25] . It is not clear whether the inhibitory effect is substrate specific or is a general effect. In comparison with calpastatin, spectrin fragments used in this study were weak inhibitors. However, spectrin concentrations are relatively high in cells, e.g., 10 μM -100 μM in red blood cells [34] . Thus, high levels of spectrin fragments may potentially be found in cells. Physiological significance of spectrin fragments inhibition at micro-molar concentrations is not clear at this time but may warrant further studies. It is tempting to speculate the following. A frequently-encountered mechanism of enzymatic activity in neurons is the negative feedback regulation [35] . It is possible that spectrin breakdown products exert a negative feedback signal toward calpain activity, but not caspase activity. The appearance of non-erythroid spectrin breakdown products in cerebral fluid is considered as an early event in neural cell pathology [16, 20] . Accumulation of spectrin breakdown products may lead to inhibition of the calpain activity, thus preventing further disruption of the cytoskeleton. Future experimentation may provide insights on this potential mechanism of calpain on spectrin. In addition to potential physiological significance of the inhibitory activity of specific spectrin fragments, our findings also allow us to suggest that, in future therapeutic agent research and development, proteins/peptides with coiled coil helical conformation should be tested for inhibitory effect on calpains. Such agents will be specific for calpains, but not for caspases. More detailed knowledge of molecular mechanism of this inhibitory effect will be needed to evaluate such possibility.
In conclusion, we have studied the effect of spectrin fragments on calpain and caspase activities. The erythroid and non-erythroid spectrin fragments were from the N-terminal region of α-spectrin, and C-terminal region of β-spectrin, both consisting of regions involved in spectrin tetramer formation. We observed that all spectrin fragments exhibited a concentration-dependent inhibitory effect on calpain, but not caspase activity. Further studies of this inhibitory effect may lead to the identification and development of new therapeutic agents specifically for calpains, but not for caspases.
